| Literature DB >> 27894304 |
Olesya Okuneva1,2,3, Zhilin Li3, Inken Körber4,5,6, Saara Tegelberg1,2,3, Tarja Joensuu1,2,3, Li Tian3,7, Anna-Elina Lehesjoki1,2,3.
Abstract
Progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1) is an autosomal recessively inherited childhood-onset neurodegenerative disorder, characterized by myoclonus, seizures, and ataxia. Mutations in the cystatin B gene (CSTB) underlie EPM1. The CSTB-deficient (Cstb -/- ) mouse model recapitulates key features of EPM1, including myoclonic seizures. The mice show early microglial activation that precedes seizure onset and neuronal loss and leads to neuroinflammation. We here characterized the inflammatory phenotype of Cstb -/- mice in more detail. We found higher concentrations of chemokines and pro-inflammatory cytokines in the serum of Cstb -/- mice and higher CXCL13 expression in activated microglia in Cstb -/- compared to control mouse brains. The elevated chemokine levels were not accompanied by blood-brain barrier disruption, despite increased brain vascularization. Macrophages in the spleen and brain of Cstb -/- mice were predominantly pro-inflammatory. Taken together, these data show that CXCL13 expression is a hallmark of microglial activation in Cstb -/- mice and that the brain inflammation is linked to peripheral inflammatory changes, which might contribute to the disease pathology of EPM1.Entities:
Keywords: CXCL13; Chemokine; Cystatin B; M1/M2; Macrophage; Vascularization
Mesh:
Substances:
Year: 2016 PMID: 27894304 PMCID: PMC5127053 DOI: 10.1186/s12974-016-0764-7
Source DB: PubMed Journal: J Neuroinflammation ISSN: 1742-2094 Impact factor: 8.322
Fig. 1Cytokine levels in the serum of control and Cstb mice. a Concentrations of CXCL1, CXCL10, CXCL13, IL-1α, IL-18, and TGF-β1 at P14 and b CXCL1, CXCL10, CXCL13, TNF-α, and TGF-β1 at P30. Data are presented as mean ± SEM (n = 3–6 per genotype; *p < 0.05, **p < 0.01, ***p < 0.001)
Fig. 2Immunohistochemical detection of CXCL13 in control and Cstb mouse brain at P14. CXCL13-positive microglia are shown by double immunofluorescence staining of CXCL13 (red) with the microglial marker IBA1 (green) in the following brain areas: i piriform cortex, ii CA3 area of the hippocampus, and iii pretectum of control and Cstb mice. Representative CXCL13- and IBA1-double-positive cells in the merged image are marked with arrows. Scale bar = 50 μM
Fig. 3Immunohistochemical detection of CXCL13 in control and Cstb mouse brain at P30. CXCL13-positive microglia are shown by double immunofluorescence staining of CXCL13 (red) with the microglial marker IBA1 (green) in the cortex and cerebellum of control and Cstb mice. Representative CXCL13- and IBA1-double-positive cells in the merged image are marked with arrows. The inserts show enlargements of one double immuno-positive cell from both brain regions. Scale bar = 50 μM
Fig. 4Brain vascularization of control and Cstb mice. a Histochemical detection of brain vessels in the cortex of control and Cstb mice at P14 and P30 was performed using DAB, which detects erythrocytes based on their endogenous peroxidase expression. b Vascularization is quantified at P14 and at P30 as relative DAB-positive area in 64 images from each of four control and four Cstb brains. Data are presented as mean ± SEM (**p < 0.01, scale bar = 50 μM)
Fig. 5Flow cytometric analysis of M1 and M2 macrophages in control and Cstb spleen and brain. a Illustrative plots show the flow cytometric gating strategy of nucleated spleen cells and enriched brain mononuclear cells. (i) In the spleen, CD45+F4/80+ macrophages were divided into CD45+F4/80+MHCII+CD206− M1 and CD45+F4/80+MHCII−/+CD206+ M2 cells. (ii) In the brain, the CD45hiF4/80+ macrophage population was divided into CD45hiF4/80+MHCII+CD206− M1 and CD45hiF4/80+MHCII−/+CD206+ M2 macrophages. Ratio between M1 and M2 macrophages at P14 and P30 (M1:M2 ratio) in the b spleen (n = 6 samples) and c brain (n = 15 samples per genotype at P14 and n = 11 per genotype at P30). Data are presented as mean ± SEM (*p < 0.05, ***p < 0.001)